{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:00:14Z","timestamp":1784138414481,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","revespcardiol.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.rec.2016.05.009","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T23:28:46Z","timestamp":1469662126000},"page":"42-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study"],"prefix":"10.1016","volume":"70","author":[{"given":"Vivencio","family":"Barrios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette","family":"Kaskens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Cosin-Sales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Emilio","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilonka","family":"Zsolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valent\u00edn","family":"Fuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Gracia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rec.2016.05.009_bib0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-5273(15)31026-3","article-title":"Global burden of CVD: focus on secondary prevention of cardiovascular disease","volume":"201","author":"Bansilal","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.rec.2016.05.009_bib0190","first-page":"1","article-title":"Prescription and adherence to medical plans","year":"2015","journal-title":"European Commission. European Innovation Partnership on Active and Healthy Ageing"},{"key":"10.1016\/j.rec.2016.05.009_bib0195","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.amjmed.2011.12.013","article-title":"Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients","volume":"125","author":"Naderi","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.rec.2016.05.009_bib0200","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","article-title":"Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences","volume":"34","author":"Chowdhury","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rec.2016.05.009_bib0205","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ahj.2007.12.011","article-title":"Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease","volume":"155","author":"Ho","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.rec.2016.05.009_bib0210","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/ajhp\/60.7.657","article-title":"Meta-analysis of trials of interventions to improve medication adherence","volume":"60","author":"Peterson","year":"2003","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.rec.2016.05.009_bib0215","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rec.2016.05.009_bib0220","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(06)69252-0","article-title":"Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis (structured abstract)","volume":"368","author":"Gaziano","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.rec.2016.05.009_bib0225","doi-asserted-by":"crossref","first-page":"e007111","DOI":"10.1136\/bmjopen-2014-007111","article-title":"Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK","volume":"5","author":"Becerra","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.rec.2016.05.009_bib0230","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1185\/03007995.2011.590969","article-title":"Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach","volume":"27","author":"Zeymer","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.rec.2016.05.009_bib0235","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijcard.2015.12.015","article-title":"Effectiveness of fixed dose combination medication (\u2fffpolypills\u2fff) compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analyses of 3140 patients in six countries","volume":"205","author":"Webster","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.rec.2016.05.009_bib0240","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.rec.2016.05.009_bib0245","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high-risk patients","volume":"342","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rec.2016.05.009_bib0250","first-page":"1","article-title":"A systematic review and economic evaluation of statins for the prevention of coronary events","volume":"11","author":"Ward","year":"2007","journal-title":"Health Technol Assess (Rockv)"},{"key":"10.1016\/j.rec.2016.05.009_bib0255","first-page":"CD006870","article-title":"Statins for acute coronary syndrome (Review)","volume":"6","author":"Vale","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rec.2016.05.009_bib0260","unstructured":"Ministerio de Sanidad Servicios Sociales e Igualdad. GRD 2011 [accessed 2016 Feb 9]. Available at: http:\/\/www.msssi.gob.es\/estadEstudios\/estadisticas\/docs\/SNS2011_PESOS_COSTES_AP25_DEF.pdf"},{"key":"10.1016\/j.rec.2016.05.009_bib0265","unstructured":"BOTPLUS. Madrid: Consejo General de Colegios Oficiales de Farmac\u00e9uticos en Espa\u00f1a; 2014 [accessed 2016 Feb 9]. Available at: https:\/\/botplusweb.portalfarma.com\/"},{"key":"10.1016\/j.rec.2016.05.009_bib0270","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.rce.2011.07.007","article-title":"Morbimortalidad y consumo de recursos asociados tras s\u00edndrome coronario agudo en una poblaci\u00f3n espa\u00f1ola","volume":"211","author":"Sicras-Mainar","year":"2011","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.rec.2016.05.009_bib0275","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.recesp.2013.12.016","article-title":"Costes sanitarios y no sanitarios de personas que padecen insuficiencia cardiaca cr\u00f3nica sintom\u00e1tica en Espa\u00f1a","volume":"67","author":"Delgado","year":"2014","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.rec.2016.05.009_bib0280","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/1074248407304791","article-title":"Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials","volume":"12","author":"Saha","year":"2007","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.rec.2016.05.009_bib0285","unstructured":"Tablas de vida, Espa\u00f1a. Madrid: Instituto Nacional de Estadistica; 2012 [acccessed 2016 Feb 9]. Available at: http:\/\/www.ine.es\/jaxi\/tabla.do?path=\/t20\/p319a\/serie\/p01\/l0\/&file=01001.px&type=pcaxis&L=0"},{"key":"10.1016\/j.rec.2016.05.009_bib0290","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1177\/1741826711406616","article-title":"Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?","volume":"19","author":"Ara","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.rec.2016.05.009_bib0295","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10198-008-0126-1","article-title":"Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study","volume":"10","author":"Taylor","year":"2009","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.rec.2016.05.009_bib0300","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1161\/CIRCULATIONAHA.107.735605","article-title":"Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction medicare beneficiaries","volume":"117","author":"Choudhry","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.rec.2016.05.009_bib0305","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2013.277064","article-title":"Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD. The UMPIRE randomized clinical trial","volume":"310","author":"Thom","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.rec.2016.05.009_bib0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.g3318","article-title":"Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care","volume":"348","author":"Selak","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.rec.2016.05.009_bib0315","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1177\/2047487314530382","article-title":"A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk","volume":"22","author":"Patel","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.rec.2016.05.009_bib0320","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaboration AT. Collaborative overview of randomised trials of antiplatelet therapy\u2fffI: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists\u2fff Collaboration","volume":"308","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.rec.2016.05.009_bib0325","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1185\/030079902125000787","article-title":"Treatment with atorvastatin to the National Cholesterol Educational Program goal versus \u2fffusual\u2fff care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study","volume":"18","author":"Athyros","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.rec.2016.05.009_bib0330","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Montalescot","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rec.2016.05.009_bib0335","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.recesp.2015.04.018","article-title":"Interhospital variability in drug prescription after acute coronary syndrome: insights from the ACDC study","volume":"69","author":"Ferreira-Gonz\u00e1lez","year":"2016","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.rec.2016.05.009_bib0340","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijcard.2014.09.029","article-title":"Real-life use of the polypill components (ASA+ACEI+statins) after an acute coronary syndrome and long-term mortality","volume":"177","author":"Oliveras Vil\u00e0","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.rec.2016.05.009_bib0345","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/bmj.330.7504.1366","article-title":"Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis","volume":"330","author":"Hippisley-Cox","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.rec.2016.05.009_bib0350","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jacc.2014.08.021","article-title":"A polypill strategy to improve adherence: results from the FOCUS project","volume":"64","author":"Castellano","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rec.2016.05.009_bib0355","unstructured":"Bansilal S, Castellano J, Wei H, Vinado E, Freeman A, Spettell C. Assessing the impact of medication adherence on long-term outcomes post myocardial infarction. ESC Congress 365. 2014 [accessed 2016 Feb 9]. Available at: http:\/\/congress365.escardio.org\/Search-Results?vgnextkeyword=C365PRESENTATION106365#.Vq-ABNLhDGg"},{"key":"10.1016\/j.rec.2016.05.009_bib0360","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1186\/s13063-015-0956-y","article-title":"Implementing Kanyini GAP, a pragmatic randomised controlled trial in Australia: findings from a qualitative study","volume":"16","author":"Liu","year":"2015","journal-title":"Trials"}],"container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585716301517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585716301517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T16:39:57Z","timestamp":1568219997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1885585716301517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1885585716301517"],"URL":"https:\/\/doi.org\/10.1016\/j.rec.2016.05.009","relation":{},"ISSN":["1885-5857"],"issn-type":[{"value":"1885-5857","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rec.2016.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.recesp.2016.05.011","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Sociedad Espa\u00f1ola de Cardiolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}